ATH 25.0% 0.3¢ alterity therapeutics limited

Ann: ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder, page-8

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,008 Posts.
    lightbulb Created with Sketch. 209
    From what I read, this is the 1st participant with advanced MSA undertaking trial for 12 mths....with up to 14 others yet to enrol.

    The randomized trial has only a handful of participants and Stamler reckons we will get results from advanced trial b4 the ra
    ndomized trial.

    Long wait. Hopefully some updates along the way?
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.